{"id":898976,"date":"2025-10-22T16:33:56","date_gmt":"2025-10-22T20:33:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/"},"modified":"2025-10-22T16:33:56","modified_gmt":"2025-10-22T20:33:56","slug":"inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/","title":{"rendered":"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n \u2013 Event to be webcast live on Thursday, October 23, 2025<\/span> at 1:30 p.m. PT<\/span> \u2013<\/i>\n <\/p>\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Oct. 22, 2025<\/span><\/span> \/PRNewswire\/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025<\/span> at 1:30 p.m. Pacific Time<\/span> to provide topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. The Company will also provide an update on the ongoing expansion trials investigating\u00a0ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma.<\/p>\n

\n

\n
\n \"Inhibrx,
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Investors may join via the web: https:\/\/app.webinar.net\/RdZmlEPaEyw<\/a>\u00a0or may listen to the call by dialing (1-888-880-3330). Please refer to Inhibrx Biosciences, Inc. or the conference ID 9577647 when calling in. Following the webcast, the presentation may be accessed through a link on the investors section of Inhibrx’s website at https:\/\/inhibrx.com\/inhibrx-biosciences-inc-investors\/events-and-presentations<\/a>. The webcast will be available for 60 days following the event. Following the presentation, Inhibrx will update its corporate presentation within the “Investors” section of its website at www.inhibrx.com<\/a>.<\/p>\n

\n About ozekibart (INBRX-109)
<\/b>Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. In January 2021<\/span>, the FDA granted Fast Track designation to ozekibart for the treatment of patients with metastatic or unresectable conventional chondrosarcoma, and, in November 2021<\/span>, the FDA granted orphan drug designation to ozekibart for chondrosarcoma.<\/p>\n

In June 2021<\/span>, Inhibrx initiated a randomized, blinded, placebo-controlled, registration-enabling Phase 2 trial of ozekibart in metastatic, unresectable conventional chondrosarcoma.<\/p>\n

Additionally, in Phase 1\/2 trials, Inhibrx is investigating ozekibart in colorectal cancer in combination with FOLFIRI and Ewing sarcoma in combination with irinotecan\/temozolomide, as well as other tumor types.<\/p>\n

\n About Inhibrx Biosciences, Inc.<\/b>\n <\/p>\n

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024<\/span> as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences’ current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit www.inhibrx.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the clinical development of ozekibart. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx’s business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; results from preclinical studies or early clinical trials not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of its therapeutic candidates that may limit their development, regulatory approval and\/or commercialization; the potential for its programs and prospects to be negatively impacted by developments relating to its competitors, including the results of studies or regulatory determinations relating to its competitors; the timing or likelihood of regulatory filings and approvals and regulatory developments in the U.S. and foreign countries; the successful commercialization of its therapeutic candidates, if approved; an accelerated development or approval pathway may not be available for ozekibart or other therapeutic candidates and any such pathway may not lead to a faster development process; it may not realize the benefits associated with orphan drug designation, including that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; and other risks described from time to time in the “Risk Factors” section of its filings with the U.S. Securities and Exchange Commission, including those described in its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K as filed from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update\u00a0these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n

Investor and Media Contact:<\/p>\n

\n Kelly Deck<\/span>, CFO
ir@inhibrx.com<\/a>
858-795-4260<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion-cohorts-302591875.html<\/a><\/p>\n

SOURCE Inhibrx Biosciences, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire \u2013 Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT \u2013 SAN DIEGO , Oct. 22, 2025 \/PRNewswire\/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m. Pacific Time to provide topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. The Company will also provide an update on the ongoing expansion trials investigating\u00a0ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan … <\/p>\n

Continue reading “Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898976","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire \u2013 Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT \u2013 SAN DIEGO , Oct. 22, 2025 \/PRNewswire\/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m. Pacific Time to provide topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. The Company will also provide an update on the ongoing expansion trials investigating\u00a0ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan … Continue reading "Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T20:33:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts\",\"datePublished\":\"2025-10-22T20:33:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/\"},\"wordCount\":980,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1063194\\\/inhibrx_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/\",\"name\":\"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1063194\\\/inhibrx_Logo.jpg\",\"datePublished\":\"2025-10-22T20:33:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1063194\\\/inhibrx_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1063194\\\/inhibrx_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/","og_locale":"en_US","og_type":"article","og_title":"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - Market Newsdesk","og_description":"PR Newswire \u2013 Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT \u2013 SAN DIEGO , Oct. 22, 2025 \/PRNewswire\/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m. Pacific Time to provide topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. The Company will also provide an update on the ongoing expansion trials investigating\u00a0ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan … Continue reading \"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-22T20:33:56+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts","datePublished":"2025-10-22T20:33:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/"},"wordCount":980,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/","name":"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg","datePublished":"2025-10-22T20:33:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898976"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898976\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}